Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 442Rectal Neoplasms 209Colonic Neoplasms 202Pancreatic Neoplasms 133Stomach Neoplasms 117Neoplasm Metastasis 86Esophageal Neoplasms 57Carcinoma, Hepatocellular 41Adenocarcinoma Of Esophagus 37Neoplasms 36Cholangiocarcinoma 27Biliary Tract Neoplasms 23Gastrointestinal Neoplasms 20Gallbladder Neoplasms 20Adenocarcinoma 19Carcinoma, Non-Small-Cell Lung 16Esophageal Squamous Cell Carcinoma 15Liver Neoplasms 14Bile Duct Neoplasms 14Digestive System Neoplasms 9Parkinson Disease 4, Autosomal Dominant Lewy Body 8Colorectal Cancer Metastatic 8Appendiceal Neoplasms 7Peritoneal Neoplasms 6Ovarian Neoplasms 6Intestinal Neoplasms 6Carcinoma 6Breast Neoplasms 6Lung Neoplasms 5Carcinoma, Renal Cell 5

Interventions

xaliproden 2Polyamines 1Oxaliplatin 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Paresthesia × Leucovorin × Gastrointestinal × Clear all
NCT00305188 2016-05-04

Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.

Sanofi

Phase 3 Completed
879 enrolled
Gastrointestinal

Neoplasm Metastasis, Paresthesia, Colorectal Neoplasms, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡